Despite the reports of elevated levels of LTα and LTβ expression in the synovium of RA patients [5,6,28], as well as the presence of lymphoid aggregates, targeting of the LT pathway with pateclizumab did not have insignificant treatment effects compared to adalimumab. Here, LTB is linked to rheumatoid arthritis.